NCT04808999View on ClinicalTrials.gov

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

April 12, 2024

Study Completion Date

April 30, 2029

Conditions

Squamous Cell Carcinoma

Interventions

DRUG

Pembrolizumab Injection

200 mg IV infusion

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Diwakar Davar

OTHER